Holen Sie sich die Stockscreener-App
10.41
2.87%
0.29
Handel nachbörslich:
10.37
-0.04
-0.38%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$10.12
Offen:
$10.16
24-Stunden-Volumen:
8.29M
Relative Volume:
0.68
Marktkapitalisierung:
$12.22B
Einnahmen:
$14.33B
Nettoeinkommen (Verlust:
$-3.79B
KGV:
-3.2839
EPS:
-3.17
Netto-Cashflow:
$1.84B
1W Leistung:
+18.97%
1M Leistung:
+14.14%
6M Leistung:
-3.61%
1J Leistung:
-10.03%
1-Tages-Spanne:
$10.10
$10.44
1-Wochen-Bereich:
$8.80
$10.44
52-Wochen-Spanne:
$6.85
$13.55
Viatris Inc Stock (VTRS) Company Profile
Firmenname
Viatris Inc
Sektor
Telefon
(724) 514-1465
Adresse
1000 MYLAN BOULEVARD, CANONSBURG
Vergleichen Sie VTRS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
10.41 | 11.50B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
152.44 | 66.04B | 9.39B | 2.61B | 2.22B | 5.81 |
|
TAK
Takeda Pharmaceutical Co Adr
|
14.77 | 45.57B | 29.98B | 958.27M | 5.31B | 0.2964 |
|
HLN
Haleon Plc Adr
|
9.69 | 42.50B | 14.35B | 1.85B | 0 | 0.4023 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
17.21 | 18.84B | 16.54B | -1.64B | 749.00M | -1.45 |
|
UTHR
United Therapeutics Corp
|
309.72 | 13.59B | 2.99B | 1.21B | 1.13B | 25.06 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-06-06 | Eingeleitet | Goldman | Neutral |
| 2024-07-19 | Fortgesetzt | Jefferies | Buy |
| 2023-10-23 | Herabstufung | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Herabstufung | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Herabstufung | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Herabstufung | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Hochstufung | Jefferies | Hold → Buy |
| 2022-11-10 | Hochstufung | UBS | Sell → Neutral |
| 2022-11-08 | Hochstufung | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Fortgesetzt | Jefferies | Hold |
| 2022-06-14 | Eingeleitet | UBS | Sell |
| 2022-05-10 | Herabstufung | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Herabstufung | BofA Securities | Buy → Neutral |
| 2022-03-01 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Eingeleitet | Citigroup | Neutral |
| 2021-04-07 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2021-03-08 | Herabstufung | Goldman | Buy → Neutral |
| 2021-03-02 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Herabstufung | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Eingeleitet | Argus | Hold |
| 2020-12-14 | Eingeleitet | Bernstein | Mkt Perform |
Alle ansehen
Viatris Inc Aktie (VTRS) Neueste Nachrichten
VTRS Q2 Deep Dive: Pipeline Progress and Cost Discipline Drive Results Amid Industry Headwinds - ca.finance.yahoo.com
Theravance Sales Jump 83 Percent - The Motley Fool
Bruker, Viatris, Sotera Health Company, Align Technology, and Omnicell Stocks Trade Up, What You Need To Know - Yahoo Finance
Viatris first to win US approval for generic Venofer - The Pharma Letter
Brufen Maker Viatris Fails To Halt Rival's 'Brisen' TM Quest - Law360
Iron Sucrose Competition Expands With Viatris and Amphastar FDA Approvals - insights.citeline.com
Viatris wins FDA nod for generic iron sucrose injection targeting Daiichi’s Venofer - MSN
Viatris Announces Approval of First Generic Iron Sucrose Injection in the U.S. - BioSpace
Why Viatris (VTRS) Is Up 10.3% After Beating Q2 Estimates and Securing FDA Generic Win - simplywall.st
Ampicillin Market Driven by Rising Bacterial Infections - openPR.com
Sector Update: Health Care - MarketScreener
Merz Asks UPC To Bar Viatris Generic MS Drug - Law360
Why Viatris (VTRS) Stock Is Up Today - Yahoo Finance
Viatris Shares Climb Following FDA Clearance of First Generic Iron Sucrose Injection - MSN
Viatris's Generic Iron Sucrose Injection Approval: A Strategic Win for Market Share and Cost-Saving in Healthcare - AInvest
Viatris stock rises after FDA approval of first generic iron sucrose - Investing.com
FDA approves Viatris’ first generic iron sucrose injection for anemia By Investing.com - Investing.com Australia
FDA approves Viatris’ first generic iron sucrose injection for anemia - Investing.com
Viatris announces FDA approval for Iron Sucrose Injection - TipRanks
Carpmaels and A&O Shearman file first SPC suit at UPC for Merz against Viatris - JUVE Patent
Viatris Inc. Reports Strong Q2 2025 Results - TipRanks
EpiPen patent expiry opens new era for innovation - MSN
Viatris Earnings Call: Growth Amid Challenges - The Globe and Mail
Viatris aims for top-half 2025 revenue and EPS guidance while advancing late-stage pipeline - MSN
Research Alert: CFRA Keeps Sell Opinion On Shares Of Viatris Inc. - 富途牛牛
Goldman Sachs Adjusts Price Target on Viatris to $11 From $10, Maintains Neutral Rating - MarketScreener
Will Viatris’ (VTRS) Leadership Moves and Steady Outlook Signal Resilience or Ongoing Transition? - simplywall.st
Viatris Inc. (NASDAQ:VTRS) Q2 2025 Earnings Call Transcript - Insider Monkey
Viatris: Q2 Earnings Snapshot - Connecticut Post
Viatris To Seek FDA Approval For MR-141 In Presbyopia In 2H, 2025Did The Stock Catch Your Eye? - RTTNews
Viatris Inc (VTRS) Q2 2025 Earnings Call Highlights: Strategic Growth Amid Revenue Challenges By GuruFocus - Investing.com Canada
Viatris Reports Mixed Q2 Earnings Amid Pipeline Progress and Operational Challenges - AInvest
Viatris 2025 Q2 Earnings Narrowed Losses Amid Revenue Decline - AInvest
Research Alert: Viatris Reports Q2 Top And Bottom-line Beats - 富途牛牛
Viatris Inc. (VTRS) Stock Forecasts - Yahoo Finance
Viatris Earnings: Solid Results Lift Shares, but We Think There Is a Lot More Upward Momentum Left - Morningstar
Divestitures Muddy Viatris' 2025, but New Launches and Pipeline Support Our Outlook - Morningstar
Xanax-maker Viatris beats quarterly profit, revenue estimates; shares rise - whbl.com
Viatris Inc. stock rises Thursday, outperforms market - MarketWatch
Viatris' Investment Prospects: Navigating Business Model Concerns and Analyst Expectations - AInvest
Viatris Q2 Revenue Beats Expectations, Stock Surges 5.6% YoY Decline - AInvest
Viatris (NASDAQ:VTRS) Beats Q2 Sales Targets, Stock Soars - TradingView
Earnings call transcript: Viatris beats Q2 2025 estimates, stock rises - Investing.com
Earnings call transcript: Viatris beats Q2 2025 estimates, stock rises By Investing.com - Investing.com Canada
Viatris Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Viatris Inc. shares rise 5.20% intraday after beating quarterly profit and revenue estimates. - AInvest
Viatris Q2 Earnings & Revenues Beat Estimates, Shares Rise - AInvest
Viatris Expects Mid-2025 Revenue and EPS Guidance, Advances Late-Stage Pipeline - AInvest
Viatris (VTRS) Q2 2025 Earnings: Navigating Regulatory Challenges and Strategic Shareholder Returns - AInvest
Viatris Q2 2025: Unraveling Contradictions in Tariffs, Growth Strategies, and Market Opportunities - AInvest
Viatris Stock Rises as Q2 Earnings & Revenues Beat Estimates - TradingView
Finanzdaten der Viatris Inc-Aktie (VTRS)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.52%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):